Skip to Content

Research & Funding

Past Other NCI & NIH InitiativesRSS

This page lists past other NCI and NIH cancer imaging initiatives, including grant mechanisms.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • PA-09-042: Mentored Clinical Scientist Research Career Development Award (K08)

    • Release Date: December 11, 2008
    • Application Receipt Date: Multiple dates, see announcement
    • Expiration Date: January 8, 2012
    • Contacts:

      Dorkina Myrick, M.D., Ph.D. (NCI), Phone: 301-496-8580, Email:

    The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. Individuals with a clinical doctoral degree interested in pursuing a career in patient-oriented research should refer to the NIH Mentored Patient-Oriented Research Career Development Award (K23).

    An award provides support for salary and research-related costs. The amount funded as salary for a career development award varies among the NIH participating Institutes and Centers (ICs). Therefore, the applicant is strongly advised to contact the relevant IC for any distinct guidelines, requirements, and allowable funds (

    See full description in NIH Guide:PAR-09-042

  • PA-09-004 & PA-09-005: Understanding the effects of emerging cellular, molecular, and genomic technologies on cancer health care delivery (R01) & (R21) (NCI)

    • Release Date: October 06, 2008
    • Application Receipt Date: Standard dates apply
    • Expiration Date: January 8, 2012
    • Contacts:

      Andrew Freedman, Ph.D., NCI, Phone: 301-435-6819, Email:

    The purpose is to invite applications for health services research addressing utilization of emerging cellular, molecular, and genetic or genomic (CMG) technologies in cancer care. The studies will assess CMG technologies in relation to: quality of care; organizational barriers and change factors in utilization; cost and cost-effectiveness; disparities in access and efficacy; monitoring of cross-sectional patterns of care and time trends; impact on existing standards of care, and; influence on cancer outcomes such as incidence, progression, mortality, survival, and quality of life. This funding opportunity specifically encourages research on commercially available CMG clinical tools already in use, as well as experimental tools in the later stages of development and/or in the regulatory approval pipeline.

    See full description in NIH Guide: R01 PA-09-004; R21 PA-09-005

  • PAR-08-120: Cancer Education Grants Program (R25)

    • Release Date: March 28, 2008
    • Application Receipt Date: Standard dates apply
    • Expiration Date: September 8, 2011
    • Contacts:

      Lester Gorelic, Ph.D., Tel: (301) 496-8580; Email:

    This Funding Opportunity Announcement (FOA) uses the NIH Research Education (R25) grant mechanism to support the following types of programs: innovative educational programs intended to motivate biomedical and other health science students to pursue cancer related careers; short courses to update cancer research scientists in new scientific methods, technologies and findings; training of cancer care clinicians and community health care providers in evidence-based cancer prevention and control approaches; development of effective innovative education (dissemination) approaches to translate knowledge gained from science (discovery) into public health and community applications (delivery).

    Because the nature and scope of the proposed research education program will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

    The total project period for an application submitted in response to this funding opportunity may not exceed five years. Direct costs are limited to $300,000 per year.

    See full description in NIH Guide:PAR-08-120

  • PA-08-098: Functional Links between the Immune System, Brain Function and Behavior (R21)

    • Release Date: March 04, 2008
    • Application Receipt Date: Standard dates
    • Expiration Date: May 17, 2011
    • Contacts:

      Paige McDonald, Ph.D., MPH, Phone: 301-435-5037, Email:

    The potent effects of neuroimmune molecules in the brain are mediated through multiple signaling pathways. However, details regarding the extent, routes, or mechanisms whereby immune signaling affects the brain in either normal conditions or during immune challenge and inflammation are largely unexplored. The purpose of this FOA is to identify research opportunities that may help to bridge the gap in understanding how immune cells and their mediators affect brain development, function and behaviors related to cognition and mood.

    See full description in NIH Guide:PA-08-098

  • Nanoscience and Nanotechnology in Biology and Medicine (R01: PAR-08-052); (R21: PAR-08-053)

    • Release Date: December 18, 2007
    • Application Receipt Date: Standard dates apply
    • Expiration Date: January 8, 2011
    • Contacts:

      Piotr Grodzinski

    This funding opportunity (FOA) is aimed at enhancing nanoscience and nanotechnology research focused on problems in biology and medicine. Nanoscience and nanotechnology refer to research and development on the understanding and control of matter at a length scale of approximately 1 - 100 nanometers, where novel properties and functions occur because of the size. The National Cancer Institute (NCI) is interested in: 1. Early detection of the disease using imaging, 2. In vitro early diagnostics: multiplexed sensitive and specific sensors, 3. Multi-functional therapeutics and localized therapy delivery, and 4. Tools and approaches to interrogate, understand, and manipulate single cells, structures , and molecules.

    URLs: (R01) (R21)

  • PAR-08-055: Cancer Prevention Research Small Grant Program (R03)

    • Release Date: December 17, 2007
    • Application Receipt Date: See below
    • Expiration Date: December 10, 2010
    • Contacts:

      Lynn Sobara, Ph.D., Tel: (301) 435-0584; Email:

    • Application Receipt Dates: March 19, July18, December 19, 2008; March 20, July 17, December 18, 2009; March 19, July 19, December 9, 2010

    This Funding Opportunity Announcement is designed to enhance the basic and applied cancer prevention research. The National Cancer Institute (NCI) invites applications that propose small and time-limited projects pertinent to the development of cancer chemoprevention agents, biomarkers for early cancer detection, cancer-related nutrition science, and/or clinical prevention studies that focus on specific target organs. Proposed projects may involve basic and/or translational research and/or human subjects-oriented research.
    Budgets for direct costs of up to $50,000 per year may be requested for a maximum of $100,000 direct costs over a 2-year (maximum time length) project period.
    Among the Early Cancer Detection topics mentioned in the specific areas of research is imaging technology. The scope of the funding mechanism includes pilot or feasibility studies; secondary analyses of existing data; small, self-contained research projects; development of research methodologies; and development of new research technologies.

    See full description in NIH Guide:PAR-08-055


    • Release Date: August 08, 2007
    • Application Receipt Date: January 28, 2008
    • Expiration Date: January 29, 2008
    • Contacts:

      Linda Brady, Ph.D., Tel 301-443-3563; E-mail:

    • Letters of Intent Receipt Date: December 28, 2007

    The purpose of the FOA, issued by the NIDA, NINDS, NIA, and NIMH, is to facilitate collaborations to extend the utility of positron emission tomography (PET) or single photon emission tomography (SPECT) radioligands in the study of brain and other organ systems to diseases beyond those for which the ligand was originally developed. An example might be the use of radioligands synthesized for probing brain systems in substance abuse for the investigation of other diseases such as cancer, schizophrenia, or obesity, or of organs other than the brain, e.g., heart, kidney, adrenal gland, ovary. Similarly, radioligands developed in a patient population afflicted with a specific disease or condition might be applied to other clinical populations with different conditions or diseases. Very often, PET or SPECT radioligands are developed at a single site with a single intended application in mind. This FOA seeks to encourage collaborations between sites that develop and use PET and/or SPECT radioligands for the purpose of expanding the range of ligand applications as well as sharing the ligands themselves or the procedures used in their development/synthesis. The overall goal of this solicitation is to optimize the utility of PET/SPECT radiotracers across organ systems and diseases and between and among sites in human subjects.

    See full description in NIH Guide: RFA-DA-08-001


    • Release Date: August 03, 2007
    • Application Receipt Date: January 18, 2008, September 18, 2008, January 21, 2009, and September 21, 2009
    • Expiration Date: September 22, 2009
    • Contacts:

      Jennifer Couch, Ph.D., Tel: (301) 435-5226;; Email:

    The NIH Blueprint for Neuroscience Research is a collaborative effort among the NIH Office of the Director and 15 Institutes and Centers to accelerate the pace of discovery and understanding in neuroscience research (for details see the following: This FOA is affiliated with the Neuroscience Blueprint, with Institutes and Centers participating independently, and with participation by Institutes that are not part of the Neuroscience Blueprint. The purpose of this FOA is to encourage researchers to use the caBIG™ and BIRN infrastructures to share data and tools by federating new software tools under these infrastructures or using the infrastructure to federate significant data sets. Awards issued under this FOA will NOT provide support to develop the tools or to measure data. The goal is to make these tools/data broadly available to other researchers.

    See full description in NIH Guide: PAR-07-426


    • Release Date: July 27, 2007
    • Application Receipt Date: September 28, 2007, September 18, 2008, September 18, 2009
    • Expiration Date: September 19, 2009
    • Contacts:

      Suresh Mohla, Ph.D.; Phone: 301-435-1878; E-mail:

    • Letters of Intent Receipt Date(s): August 27, 2007, August 16, 2008, August 17, 2009

    This Funding Opportunity Announcement issued by the National Heart, Lung, and Blood Institute (NHLBI), in conjunction with other Institutes, solicits Research Project Grant (R01) applications from qualified researchers to investigate the biology of the lymphatic system and potential new therapeutic implications. The purpose of this program announcement is to stimulate research on the biology of the lymphatic system at all biologic levels: molecular, cellular, tissue, organ, and whole body levels. Further, it includes research on innovations for identifying and intervening in lymphatic diseases across all age groups and disease states. Examples of potential areas of research pertinent to NCI participation in PAR-07-420 are listed in the announcements. Among the examples are a) Molecular characterization and comparison of normal and tumor lymphatic endothelia and their component cells, including identifications of molecular markers, secreted factors, and/or receptors;b) Determination of the functional status of tumor lymphatic vessels, e.g. the uptake and transport of fluid and macromolecules; c)Study of the interplay between angiogenesis and lymphangiogenesis; d) Design and validation of imaging modalities to visualize normal and tumor lymphatics.

    See full description in the NIH Guide: PAR-07-420

    See description of NCI areas of research interest: NOT-CA-07-022


    • Release Date: July 25, 2007
    • Application Receipt Date: See dates below
    • Expiration Date: May 15, 2010
    • Contacts:

      Zohara Cohen, Ph.D., Tel: 301-451-4778; E-mail:

    • Letters of Intent Receipt Date(s): August 24, 2007; December 15, 2008; April 15, 2008; August 15, 2008, December 15, 2009; April 15, 2009; August 15, 2009; December 15 2010; and April 14, 2010
    • Application Submission/Receipt Date(s): September 24, 2007; January 15, 2008; May 15, 2008; September 15, 2008, January 15, 2009; May 15, 2009; September 15, 2009; January 15 2010; and May 14, 2010

    This FOA intends to support modification and enhancement of existing neuroimaging informatics tools and resources that are hosted or being considered for inclusion into the NIH Neuroimaging Informatics Tools and Resources Clearinghouse (NITRC,, public release scheduled for October 2007). Examples of such tools include image segmentation, image registration, image processing pipelines, statistical analysis packages, spatial alignment and normalization algorithms, and data format translators. Resources include well-characterized test datasets, data formats, and databases, among others.

    See full description in NIH Guide: PAR-07-417